Notably, we also found that 6 immune checkpoints were significantly upregulated in the high-glioma-risk group, including CD274, CTLA4, LAG3, LGALS9, PDCD1, and PDCD1LG2 (Fig. 5C). This evidence concerns the gene CTLA4 and central nervous system cancer.